Unrecognized myocardial scar by late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) is strongly associated with cardiac event in patients with stable coronary artery disease. The purpose of this study was to evaluate the prognostic impact of unrecognized non-infarct-related LGE (non-IR-LGE) in patients with acute myocardial infarction (AMI). 
Introduction
Accurate risk stratification is very important for the management of patients with acute myocardial infarction (AMI) to improve outcomes. High Killip classes, elevated creatinine phosphokinase level, and older age are well-known poor prognostic factors in AMI patients. [1] [2] With regard to angiographic findings, the presence of multi-vessel disease (MVD) with and without chronic total occlusion lesion in non-infarct-related (non-IR) arteries is also associated with poor outcomes in AMI patients. [3] [4] [5] In addition, recurrent AMI, which is frequently associated with MVD, is a disastrous condition and can results in severely impaired left ventricular (LV) function and shock states, which lead to high rate of in-hospital mortality. [6] [7] Late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) is a useful non-invasive cardiac imaging for the detection of myocardial infarction (MI). In addition, LGE MRI can provide accurate assessment of MI size and myocardial viability in AMI patients, which is closely associated with patient outcomes. [8] [9] [10] Previous reports demonstrated that the prevalence of unrecognized MI incidentally found by cardiac MRI was more frequent than expected in subjects without underlying cardiac disease and was associated with poor outcomes. 11, 12 Furthermore, the presence of unrecognized MI detected by cardiac MRI provides incremental prognostic value for predicting poor prognosis in patients with a clinical suspicion of coronary artery disease (CAD) but without a history of MI. 13 However, the prognostic impact of unrecognized myocardial scar in non-IR coronary territories detected by cardiac MRI remains unknown in patients with a first clinical episode of AMI. Accordingly, we evaluated the prognostic impact of unrecognized non-IR myocardial scar in patients with a first clinical episode of AMI.
Methods

Study population
We retrospectively studied 269 patients with a first clinical episode of AMI who underwent successful percutaneous coronary intervention (PCI) and who underwent cardiac MRI within 6 weeks after the onset of AMI from January 2007 to June 2015. Patients were recruited from three hospitals in Mie prefecture in Japan (Mie University Hospital, Nagai Hospital and Matsusaka Central Hospital). In these three cooperative hospitals, cardiac MRI examination has been performed within 2 months after primary PCI in AMI patients without exclusion criteria for routine clinical setting to investigate the infarct size and LV function. Patients with any of following conditions were excluded: (i) previous coronary artery bypass grafting, (ii) suspected or known cardiomyopathy, (iii) patients with previous MI, (iv) patients with failed PCI, and (v) AMI patients without primary PCI. In addition, patients with contraindications for contrastenhanced MRI including low estimated glomerular filtration rate below 30 mL/min/1.73 m 2 , claustrophobia and allergy to gadolinium were not enrolled in this study (see Supplementary file online). The current study was approved by the institutional review board of Mie University.
Emergency coronary angiogram and PCI for AMI
AMI was defined using the criteria of the third universal definition of MI. 14 All patients included in this study underwent emergency coronary angiogram and received primary PCI for the culprit artery at physicians' discretion. The coronary angiogram images were interpreted independently by two cardiologists, and MVD was defined as the presence of >50% stenosis in > _2 major epicardial coronary arteries or their major branches from two orthogonal views. 15 In the case of MVD, elective PCI of the non-IR artery was performed after cardiac MRI examination.
Cardiac magnetic resonance imaging
Cardiac MRI was performed in all patients in the supine position and was done using 1.5 Figure 1) . Initial scout images were obtained in three orthogonal directions to determine the position of the heart and diaphragm. Steady-state free precession cine MR images were obtained on the vertical long-axis and with four-chamber views, followed by acquisition of short-axis cine MR images covering the entire LV. Acquisition parameters included repetition time of 3.2 ms, echo time of 1.6 ms, flip angle of 55 , matrix of 190 Â 190, field of view of 350 mm, section thickness of 10 mm, and SENSE factor of 2. For the assessment of myocardial oedema, T2-weighted breath-hold black-blood triple-inversion fast spin echo images were obtained with the following parameters: repetition time of two cardiac cycles, echo time of 80 ms, flip angle of 90 , matrix of 240 Â 164, field of view of 380 mm and slice thickness of 8 mm. T2-weighted MR imaging were acquired on short-axis planes (four slices) and horizontal long-axis plane (one slice).
LGE MRI were acquired 10 min after intravenous administration of 0.15 mmol/kg of gadopentetate dimeglumine (Magnevist: Schering AG, Berlin, Germany). Segmented inversion-recovery three dimensional gradient-echo sequences were used with the following parameters: repetition time of 3.9 ms, echo time of 1.2 ms, flip angle of 15 , acquisition matrix of 224 Â 157, reconstruction matrix of 512 Â 512, field of view of 380 mm, section thickness of 10 mm and SENSE factor of 2. Inversion time was adjusted to null the signal of normal myocardium.
Cardiac MRI analysis
Analysis of MR images was performed by the consensus of two experienced observers who were blinded to patient history and clinical follow-up data, and imaging data were analysed on a commercially available post-processing workstation.(CMR42, Circle Cardiovascular Imaging Inc. Calgary, Canada) On cine MRI, epicardial and endocardial borders at end systole and end diastole were traced manually using short-axis images to determine left and right ventricular end-diastolic volume, endsystolic volume and LV mass, which were indexed to body surface area when appropriate. LV ejection fraction (LVEF) was measured by the standard Simpson's rule. Right ventricular EF was also measured by the standard Simpson's rule. Further assessment of LV regional wall motion abnormalities in the 16 segment model and assessment for myocardial oedema and LGE were performed. 16 For the assessment of myocardial oedema on T2-weighted MR images, the ratio of the mean signal intensity of myocardium when compared with that of the skeletal muscle was used and oedema was considered to be present if the signal intensity ratio was more than 2.0. 17 Bright signal on T2-weighted MR images because of slow chamber blood flow was excluded from the analysis by referencing cine MR images acquired at the same slice location. Infarcted myocardium was considered if the signal intensity was more than 5 standard deviation above remote normal myocardium in LGE images and microvascular obstruction (MO) which was defined visually as the hypointense core within the infarcted zone were included for LGE area. All LGE images were analysed in a session separate from that for the interpretation of segmental wall motion. After evaluating for the presence or absence of LGE, the aetiology of LGE was also determined. Infarct-related-LGE (IR-LGE) was defined if LGE was present in the high intensity area on T2-weighted images. Unrecognized non-IR-LGE (non-IR-LGE) was defined if LGE was located in the area of non-infarct-related artery without the high intensity area by T2-weighted images. 18 Both IR-LGE and non-IR-LGE in weight (g), volume (mL) and percentage (%) of LV mass were calculated separately from the summation of the area with LGE and MO within each segment of the short-axis images, multiplied by the slice thickness to cover entire left ventricle. Viability was defined as transmural extent of hyperenhancement <50%. Total LGE volume was defined as the sum of the IR-LGE volume and non-IR-LGE volume.
Patient follow-up
At least 3 months after the onset of first clinical episode of AMI, outcome data were collected via patient interviews at the outpatient clinic, hospital chart reviews or telephone interviews with the patient or close relatives. Primary end point was major adverse cardiac events (MACE), including cardiovascular death, non-fatal MI, unstable angina pectoris requiring revascularization, fatal arrhythmia, and hospitalization for heart failure (HF). Cardiovascular death was defined as death from fatal MI, HF and fatal arrhythmia, or sudden unexpected death occurring without another explanation. When a patient experienced MACE several times, the first event was chosen for analysis. Follow up rate was 100% in this study population.
Statistical analysis
Continuous variables with normal distributions are expressed as mean and standard deviation, and those without normal distributions are expressed as median and interquartile range. Categorical variables are expressed as number and proportions. The Student's t-test or Mann-Whitney rank sum test was used to assess statistical significance of continuous variables with and without normally distributed variables, and categorical variables were compared with the chi-square test. Kaplan-Meier curves were used to estimate the distribution of time to end point. Differences between timeto-event curves were compared with the log-rank test in each group. The association of clinical, angiographic and cardiac MRI findings with outcomes was investigated with a Cox proportional hazards model using multivariate procedures. The Cox proportional hazards model was used to estimate the risk of a given variable as expressed by a hazard ratio (HR) with corresponding 95% confidence intervals (CI). All data analysis was performed with SPSS for Windows 12.0.1 (SPSS Corp, Chicago, IL, USA). Statistical significance was defined as P < 0.05.
Results
Baseline patient characteristics
Baseline patient characteristics are summarized in Table 1 . In 269 patients, mean age was 66 ± 12 years, and 78% were male. Unrecognized non-IR LGE was found in 13.0% of patients. The prevalence of a history of CAD was significantly higher in patients with unrecognized non-IR LGE than in those without unrecognized non-IR LGE. There were no significant differences between the two groups in the other factors, including medicines at discharge used to treat AMI.
Angiographic findings
Patients with unrecognized non-IR LGE showed a significantly higher frequency of MVD when compared with those without unrecognized non-IR LGE ( Table 2) . On the other hand, the prevalence of culprit PCI was performed for the culprit lesion of occluded proximal RCA. Coronary angiography showed total occlusion of culprit RCA lesion and severe stenosis of the proximal LAD (A-C). T2-weighted imaging demonstrated the high signal intensity area in the inferior wall, which corresponded to the inferior LGE area (D and E). In addition, LGE was found in the anteroseptal wall without a high signal intensity area by T2-weighted imaging, which corresponded to the myocardium perfused by LAD (D-F).
LGE, late gadolinium enhancement. 
Cardiac MRI findings
LVEF was significantly lower in patients with unrecognized non-IR LGE than in those without unrecognized non-IR LGE ( Table 2) . IR-
LGE was visualized in all AMI patients. (Figure 1 ) The prevalence of IR-LGE without viability and of IR-LGE with MO was not different between the two groups. Furthermore, IR-LGE volume, % IR-LGE volume and total LGE volume were not significantly different between the two groups. Unrecognized non-IR LGE was associated with upstream obstructive CAD in 91.4% of cases.
Outcome data
During follow-up (median, 22 months; range, 3-95 months), 24 of the 269 patients (8.9%) experienced MACE, including 4 with cardiovascular death (3 with fatal arrhythmia), 6 with non-fatal MI, 5 with unstable angina requiring revascularization, and 9 with HF requiring hospitalization ( Table 3) . Of those all patients, 22 .9% of patients with unrecognized non-IR LGE and 6.8% of patients without unrecognized non-IR LGE experienced MACE (P < 0.01). Univariate analysis of clinical, angiographic, and MR imaging variables revealed that older age, MVD, high LV end-diastolic volume index, high RV end-diastolic volume index, high RV end-systolic volume index, the presence of non-IR LGE, and the absence of viability in the territory containing the non-IR LGE segments were significantly associated with MACE ( Table 4) . According to the Kaplan-Meier survival curve, the presence of non-IR
LGE was significantly associated with poor outcomes with a HR of 3.45 (95% CI, 1.03-11.47; P < 0.01) in patients with AMI (Figures 1 and 2) .
Cox proportional hazard regression analysis showed that the presence of unrecognized non-IR LGE, higher age and LV end-diastolic volume index were independent predictors of MACE (Table 5) . Furthermore, the presence of unrecognized non-IR LGE was the strongest independent predictor for MACE. In addition, comparison of event rate between epicardial coronary artery findings and myocardial findings in non-IR territories demonstrated in Figure 3 . Downstream myocardial finding with presence of unrecognized non-IR myocardial scar provided the higher prognostic value for predicting the occurrence of MACE compared with the upstream epicardial coronary artery disease in this study. (odds ratio 4.5, 95% CI: 1.8-11.2, P ¼ 0.002, vs. odds ratio 3.8, 95% CI: 1.5-9.7, P ¼ 0.003, respectively).
Discussion
The present study investigated the frequency of unrecognized non-IR myocardial scar and its prognostic impact in patients with a first clinical episode of AMI. The presence of unrecognized non-IR myocardial scar was the strongest independent predictor of MACE. Several previous studies demonstrated that approximately 50% of AMI patients had non-IR-CAD, which led to increased short-and long-term mortality. 19 However, these previous studies did not evaluate the status of myocardium downstream of non-IR-CAD. The present study clearly demonstrated that the presence of non-IR LGE was significantly associated with poor outcomes in patients with a first episode of acute myocardial infarction.
LGE, late gadolinium enhancement. Prognostic impact of unrecognized non infarct related myocardial scar in AMI myocardial scar has a greater impact than the presence of non-IR-CAD (namely, MVD) on patient outcomes, suggesting the importance of myocardial tissue characterization rather than the morphologic assessment of the epicardial coronary artery. In our study, 11.5% of patients with unrecognized non-IR myocardial scar experienced obvious coronary events (non-fatal MI and unstable angina pectoris requiring revascularization) during the follow-up period, which tended to be more frequent when compared with obvious coronary events in those without non-IR myocardial scar (3.0%). Kwong et al. 13 reported that the prevalence of unrecognized myocardial scar in patients with suspected CAD was 23%. They excluded the patients with acute and prior MI by history, medical record or abnormal enzyme value. There is no overlap in patient population between the study by Kwong et al. 13 And, even in the randomly chosen 70-year-old subjects, the prevalence of unrecognized myocardial scar was 19.8%. 12 We have presumed a higher incidence of unrecognized non-IR myocardial scar in this study population when compared with that in previous studies, because the present study recruited AMI patients. However, the frequency of unrecognized non-IR myocardial scar was 13.0%, which was lower than that seen in previous reports.
Increasing evidence suggests that the Japanese is less prone to subclinical atherosclerosis. 20 Further, the incidence of AMI in Japanese populations was far lower than that of patients in Western countries. 21 As mentioned above, the lower prevalence of unrecognized non-IR myocardial scar might be explained by difference in population ethnicity between studies. The incidence of unrecognized non-IR myocardial scar in Western AMI patients might be much higher than those in Japanese AMI patients. Several factors might contribute to the occurrence of unrecognized myocardial scar. Subclinical coronary plaque rupture occurs frequently, particularly in diabetic patients. Cardiac MRI may detect the myocardial sequelae of coronary plaque rupture or coronary plaque erosion that either spontaneously reperfused or that was nonocclusive. 22 In addition, MI can be present without chest pain and is then frequently unrecognized, especially in elderly patients. 23 According to previous reports, angiography does not reveal obstructive CAD in approximately 5-14% of AMI patient, so the pathophysiological processes responsible for the AMI are not immediately evident in some patients. 24, 25 The Third Universal Definition of
Myocardial Infarction has proposed a definition for MI secondary to an ischaemic imbalance in instances of myocardial injury with necrosis, where a condition other than CAD contributes to an imbalance between myocardial oxygen supply and demand. Coronary vasospasm and/or endothelial dysfunction with decreased coronary flow reserve also have the potential to cause MI. 14 In our study, unrecognized non-IR myocardial scar was not associated with upstream obstructive CAD in 8.6% of cases. These LGEs might be caused by coronary spasm, decreased coronary flow reserve, healed coronary plaque rupture, or embolism. 14, 25, 26 The volume of unrecognized non-IR LGE was significantly smaller than that of IR LGE in this study, which is consistent with findings from previous studies. 11, 27 These findings might explain why unrecognized myocardial scar escaped from clinical recognition in patients with AMI. However, even in a very small unrecognized LGE (<2% mean LV mass), LGE was associated with a >7-fold increase in MACE in patients with suspected CAD. 13 Clinically, resting thallium single photon emission computed tomography (SPECT) images have been widely used to investigate MI size and myocardial viability in AMI patients. However, SPECT images cannot detect a small amount of infarcted myocardium, because its spatial resolution is limited. 28 Cardiac MRI are more suitable for detecting small unrecognized non-IR myocardial scar when compared with SPECT, which leads to the accurate risk stratification of AMI patients. In addition, even 40% patients with non-IR LGE area without viability experienced MACE. This might strongly suggest that the viability of non-culprit myocardium associate with the prognosis. But only five patients presented non-IR LGE area without viability, detailed statistical analysis could not be performed in present study.
Various mechanisms might explain why unrecognized non-IR myocardial scar provided incremental prognostic value beyond clinical, angiographic and LV functional variables. First, the presence of unrecognized non-IR myocardial scar might represent the same situation as with recurrent AMI, which is as a disastrous condition with high inhospital morbidity and mortality. 7 Second, the presence of any LGE may be a marker of a more severe burden of coronary atherosclerosis. 13, 29 It has been demonstrated that patients with unrecognized myocardial scar assessed by cardiac MRI had higher coronary calcium, higher prevalence of atherosclerotic disease, and higher prevalence of traditional risk factors when compared with those without unrecognized myocardial scar. 27 In our study, patients with unrecognized non-IR myocardial scar had significantly higher frequency of MVD compared with those without unrecognized non-IR myocardial scar, which suggests a higher prevalence of atherosclerotic burden. Third, patients with unrecognized non-IR myocardial scar might have decreased coronary flow reserve as mentioned above, which might lead to poor outcomes. Conflicting data exist regarding treatment strategies for non-IR CAD in AMI patients and its clinical effect on outcomes, and there has been no large randomized trial designed to answer this clinically important question. 15, 30 Because of the small number of patients with unrecognized non-IR myocardial scar, it is difficult to comment on the indication for additional PCI to the artery perfusing the non-IR myocardial scar area based on our study findings. The possible benefit of additional revascularization for non-IR LGE artery on LVEF and outcomes warrants further investigation. In addition, evaluating for the presence or absence of non-IR myocardial scar or the viability of the non-IR area before PCI might help risk stratify patients and help guide the treatment plan.
Clinical implication
This study found that unrecognized non-IR myocardial scar was a strong predictor of poor outcomes when used for risk stratification in AMI patients. In addition, this study also showed the potential utility of classifying AMI patients with MVD according to the presence or absence of unrecognized non-IR myocardial scar. In addition, performing cardiac MRI in routine care to extract patients with unrecognized myocardial scar would contribute to more precise prevention CAD and detection of significant CAD.
Limitation
This study was retrospectively analysed with relatively small number of patients and short duration, which lead to the insufficient study on the effect of unrecognized non IR myocardial scar on hard end point with cardiovascular death and non-fatal MI. The AMI patients who died before cardiac MRI examination were not included in this study, suggesting that the most severe cases might be excluded from this study. Also, AMI patients with haemodynamic instability who could not undergo cardiac MRI study during the acute phase were not enrolled in this study population. These might explain why previously known prognosticators, including the presence of MVD, volume of LGE, presence of MO, decreased LVEF, and high-Killip classes, did not independently contribute to poor outcomes in the present study.
Conclusions
This study is the first report to show the prognostic importance of unrecognized non-IR myocardial scar assessed by cardiac MRI for predicting cardiac events beyond conventional clinical, angiographic, and functional predictors in patients with a first clinical episode of AMI.
Supplementary data
Supplementary data are available at European Heart JournalCardiovascular Imaging online.
